Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Few Side Effects From Long-Term Use of Combination Latanoprost Plus Timolol: Presented at ARVO By Cameron Johnston FORT LAUDERDALE, Fla -- April 30, 2008 -- One of the largest and longest safety trials ever conducted using an ocular hypotensive drug has demonstrated no increased risk of harmful side effects when the fixed-dose combination of latanoprost and timolol is used to treat open-angle glaucoma or ocular hypertension, it was reported here at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). In this study, 974 patients began treatment with a once-daily fixed-dose combination of latanoprost and timolol. Patients were evaluated at a total of 11 clinic visits spaced approximately 6 months apart. All patients had glaucoma that was not controlled adequately with timolol or another agent alone. Prior prostaglandin use was not permitted. After a mean follow-up of approximately 5 years, 23.9% of patients had at least some increase in iris pigmentation, while 61% had none. Increased iris pigmentation is a well-known side effect with latanoprost, which resolves if the drug is discontinued. Only 8 patients in total had what was considered "marked" iris pigmentation, while the others had either mild or moderate. A further side effect with latanoprost, also well documented, is an increase in eyelash length and thickness. In this study, 463 patients (47.5%) reported an increase in eyelash length. The other side effect that was measured was the increase in periorbital darkening, a condition in which the patient appears to have a suntan around the eyes. This occurred in 51 patients, of whom 39 had darkening around both eyes. These side effects were not unexpected, said John Grunden, PhD, Senior Investigator, Pfizer, Inc., New York, New York, which produces latanoprost and the fixed-dose combination of latanoprost and timolol. Dr. Grunden noted that all of these side effects are asymptomatic and are purely cosmetic. The fixed-dose combination of latanoprost and timolol was shown in this study to be safe and effective, said Dr. Grunden, and the side effects were not serious, nor were they sufficient to make the patients want to switch to another drug. The spectrum of side effects from other ocular hypotensive drugs has led scores of patients with glaucoma to stop using their medications within the first year, so any drug that is able to demonstrate minimal side effects should increase the likelihood of patient compliance, Dr. Grunden concluded. Funding for this study was provided by Pfizer, Inc. [Presentation title: 5-Year, Multicenter Safety Study of Fixed-Combination Latanoprost/Timolol (Xalacom) for Open-Angle Glaucoma (OAG) and Ocular Hypertension (OH). Abstract A64] E-mail this page to a friend or colleague! To print, use this version